Cadence Pharmaceuticals — Investor Presentation (September 2011)
22 slides from Cadence Pharmaceuticals's investor presentation, Sep 28, 2011
Slide 1: Corporate Overview
Corporate Overview Improving the lives of hospitalized patients September 2011 Exhibit 99.1
Slide 2: Caution on forward-looking statements
Caution on forward-looking statements © 2011 Cadence Pharmaceuticals, Inc. All rights reserved. This presentation includes forward-looking statements, which are based on our current beliefs and expectations. Such statements include, without limitation, statements regarding: the anticipated U.S. mark
Slide 3: Cadence: investment highlights
Cadence: investment highlights Hospital-focused specialty pharmaceutical company OFIRMEV ® launched with broad pain and fever indication in January 2011 – Rapid formulary adoption demonstrated – Established hospital sales team provides a core platform for the acquisition of additional products – Man
Slide 4: Product overview
OFIRMEV ® : product overview OFIRMEV (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New class of IV medication • non-narcotic / opioid • non-NSAID – Same formulation of IV acetaminophen marketed by
Slide 5: Broad indication supports message
OFIRMEV ® : • Significant pain relief • Reduced opioid consumption* • Improved patient satisfaction • Established safety profile Message Broad Indication • Mild to moderate pain • Moderate to severe pain with adjunctive opioids • Reduction of fever • Adults and children 2 and older indication suppor
Slide 6: Strong foundation for commercial success
OFIRMEV ® : Effective Pain Control Experienced Hospital Sales Force Economic Value strong foundation for commercial success • Sales force average >10 years hospital selling experience • Extensive relationships, significant overlap with prior territory • Substantial hospital commercial experience thr
Slide 7: Strong early launch indicators
OFIRMEV ® : strong early launch indicators* Rapid formulary adoption – On formulary in over 1,150 hospitals – Mix of formulary wins is representative of overall target market – Includes major academic medical centers and large community healthcare systems Most hospitals approved OFIRMEV without rest
Slide 8: Multi-step launch process
Hospital products: Regulatory Approval Physician Access Formulary Access Sales multi-step launch process
Slide 9: Adoption process
Phase III Increase Doses Per Patient Phase II Broaden Physician Utilization Phase I Create Access OFIRMEV ® : adoption process
Slide 10: Cadence Pharmaceuticals
cadence PHARMACEUTICALS
Slide 11: Strong revenue ramp
OFIRMEV ® : strong revenue ramp Source: Wolters Kluwer Pharma Solutions, Source® PHAST Institution. Cubist Pharmaceuticals, Inc. Form 10-Q reports. Based on Cadence comparison to other selected product launches in hospital market over period March – Aug 2011. OPAT utilization from Cubist Corporate P
Slide 12: Limitations of other IV pain therapies
Limitations of other IV pain therapies Opioids NSAIDs Sedation Nausea Vomiting Constipation Headache Cognitive impairment Respiratory depression Black Box Warning Bleeding GI complications Kidney complications Cardiovascular risks Prolonged recovery Increased length of stay Higher costs to the insti
Slide 13: Multi-modal analgesia: the norms
Pain Intensity Current US Approach Current EU Approach Multi-modal analgesia: Severe Opioids IV acetaminophen + opioids Moderate Opioids IV acetaminophen +/- opioids* Mild Opioids IV acetaminophen the norms * First post operative analgesic drug, then add opioids if necessary
Slide 14: Pivotal acute pain clinical trial
IV acetaminophen placebo p-value Sinatra Study: IV acetaminophen placebo p-value Sinatra, et al. Anesthesiology, V 102, No. 4, April 2005. Weighted sums of pain relief over 6hrs 6.6 2.2 <0.05 Patient Satisfaction (Good/excellent – hrs) 41% 23% <0.01 Morphine consumption over 24 hrs** 38.3 mg (33% )
Slide 15: Consistent opioid reduction across studies
Pain Intensity Opioid Reduction* Time p Value Consistent opioid reduction across studies Severe 33% 24h <0.01 61% 24h <0.05 Moderate 53% 0-6h 0.016 Mild 86% 24h <0.001 78% 24h <0.01 *Reduction in number of patients requiring analgesic rescue with ketorolac and fentanyl 1) Sinatra, et al, 2005; 2) Me
Slide 16: Economic value
OFIRMEV ® : economic value Placebo-controlled studies using IV acetaminophen demonstrated results that may be associated with possible hospital cost savings: – Decreased opioid consumption * • Total hip/knee replacement (1) • Total hip replacement (2, 3) • Adult tonsillectomy (4) • Endoscopic thyroi
Slide 17: IV acetaminophen: EU market leader
IV acetaminophen: Source: IMS Data *(SOM – Share of market) • >20% unit share of injectable analgesic market EU market leader
Slide 18: The UK experience: an appropriate model
The UK experience: an appropriate model UK treatment paradigms for moderate and acute pain are similar to those in the US – Higher opioid than NSAID usage – Multimodal pain therapy Perfalgan, BMY’s IV acetaminophen – Launched in 2004 – Has taken approximately 35% market share – Most share taken from
Slide 19: Oral opioids: acetaminophen combinations dominate
Oral opioids: acetaminophen combinations dominate Opioid-acetaminophen combinations Opioid-only products Opioid-NSAID combinations 73% 25% 1% Source: IMS data, 2008. 73% of oral opioid doses sold in U.S. contain acetaminophen Approximately 14.4 billion total doses sold in 2008 Acetaminophen + hydroc
Slide 20: US market opportunity
OFIRMEV ® : US market opportunity US and EU injectable analgesics markets are similarly sized Approximately 87 million IV acetaminophen units sold in Europe in 2009 Continued EU market expansion after introduction of IV acetaminophen Sources: IMS data, company estimates
Slide 21: Cadence: financial position
Cadence: financial position 12 Months Ended 12/31/10 (MM) 6 Months Ended 6/30/11 (MM) Operating expenses $ 54.9 $ 46.4 Cash, cash equivalents & short-term investments $134.1 $ 94.1 Shares outstanding 63.1 63.6
Slide 22: Product overview
OFIRMEV ® : product overview OFIRMEV (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New Class of IV Analgesic OFIRMEV launched with broad pain and fever indication in January 2011 – Rapid formulary
Cadence Pharmaceuticals — Investor Presentation (September 2011) on 6ix